Feature | Heart Valve Technology | October 15, 2015

Sapien 3 Valve Shows Favorable One-Year Results in PARTNER II Trial

Data demonstrates improved survival, low rates of stroke, paravalvular leak

PARTNER II Trial, TCT 2015, Edwards Lifesciences, Sapien 3 valve, one-year results

Image courtesy of Edwards Lifesciences

October 15, 2015 — One-year patient outcomes from the PARTNER II trial showed the low rate of 30-day complications with balloon-expandable transcatheter aortic valve replacement (TAVR) in high-risk and inoperable patients with aortic stenosis persisted with follow-up to one year.

One-year findings from the PARTNER II Sapien 3 study were presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

The initial PARTNER I trial demonstrated the early promise of TAVR with first-generation devices for high-risk (HR) and inoperable (INOP) patients. The PARTNER II Sapien 3 trial was a two-single-arm, non-randomized, historical-controlled study that utilizes the newest generation balloon-expandable TAVR device. Thirty-day outcomes, which were reported earlier this year at the American College of Cardiology (ACC) annual meeting, demonstrated very low rates of adverse events. The newest findings presented at TCT report results for the HR/INOP arm at one year.

The HR/INOP cohort of PARTNER II enrolled 583 patients (average age >80) at 29 U.S. sites with severe aortic stenosis who were deemed high-risk or inoperable for surgery. The follow-up rate at one year was 98.6 percent and the all-cause survival rate was 85.6 percent. Survival was 87.7 percent for transfemoral (TF) access procedures and 89.3 percent for high-risk patients treated by the TF route. The study also found that there was a low rate of disabling stokes at one year (2.4 percent) with no difference between HR and INOP or TF and TA.

Paravalvular aortic regurgitation also remained low, with 2.7 percent with moderate regurgitation and 29.1 percent with mild regurgitation at one year. Importantly, there was no increased mortality in the patients with mild regurgitation as compared to those with none or mild and no patient had severe regurgitation. Hemodynamic valve performance and early symptomatic improvement were also sustained at one year. All-cause mortality at 2.2 percent at 30 days and 14.4 percent at one year.

“The combination of new design features, procedural improvements, operator experience and improved patient selection have all contributed to a low rate of adverse events and a high rate of one-year survival in TAVR for high-risk and inoperable patients with severe aortic stenosis,” said study investigator, Howard C. Herrmann, M.D.  “This represents a 50 percent reduction in mortality in both HR and INOP patients as compared with the first-generation TAVR device.” Herrmann is the John Winthrop Bryfogle Professor of Cardiovascular Diseases and director of Penn Medicine’s Interventional Cardiology Program in the Perelman School of Medicine at the University of Pennsylvania.

“This one-year follow-up data support the use of TAVR as the preferred therapy in high-risk and inoperable patients with aortic stenosis,” he said.

The Sapien 3 valve was approved in Europe in January 2014 and in the United States in June 2015 for the treatment of high-risk patients with severe aortic stenosis.

The PARTNER II Sapien 3 trial was funded by Edwards Lifesciences. Herrmann reports grant/research support from Abbott Vascular, Boston Scientific, Cardiokinetix, Edwards Lifesciences, Gore, Medtronic, Mitraspan, Siemens and St. Jude Medical. He also reported equity in MicroInterventional Devices, and speaking honoraria from Edwards Lifesciences.

For more information: www.tctconference.com

Related Content

Videos | TCT | October 03, 2018
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the ex
cardiologist Ted Feldman, M.D., at TCT 2017. #TCT2018 #TCT #TCT18 TCT Late breaking trials, studies.
Feature | TCT | September 21, 2018
October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clini
Interventional cardiology, cath lab technology, TCT, transcatheter cardiovascular therapeutics. #TCT #TCT18 #TCT2018
Feature | TCT | September 14, 2018 | Dave Fornell, Editor
The volume of information attendees receive at the annual...
Videos | TCT | November 15, 2017
DAIC Editor Dave Fornell shows some of the innovations displayed on the expo floor at the 2017 Transcatheter Cardiova
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | TCT | November 09, 2017
November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has select
Key Interventional Cardiology and structural heart Technologies to Prepare for TCT 2017.
Feature | TCT | October 26, 2017 | Dave Fornell
Here is an aggregation of DAIC content for all major cardiovascular technology news and advances this past year. These...
Videos | TCT | November 18, 2016
DAIC Editor Dave Fornell takes a video tour of some of the most innovative new interventional cardiology technologies
Videos | TCT | November 05, 2015
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies pr
Videos | TCT | November 05, 2015
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 T
Amaranth Fortitute Bioresorbable stent

The Amaranth Fortitute bioresorbable stent was among several fully bioresorbing platforms discussed in sessions, late breaking trial data presentations and on the expo floor at TCT 2015.

Feature | TCT | October 19, 2015 | Tom Watson, BS, RCVT, Clinical Analyst, MD Buyline
There were several overarching technology trends seen at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) ann
Overlay Init